KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Current Assets (2018 - 2025)

Esperion Therapeutics' Current Assets history spans 8 years, with the latest figure at $462.6 million for Q4 2025.

  • For Q4 2025, Current Assets rose 36.86% year-over-year to $462.6 million; the TTM value through Dec 2025 reached $462.6 million, up 36.86%, while the annual FY2025 figure was $462.6 million, 36.86% up from the prior year.
  • Current Assets reached $462.6 million in Q4 2025 per ESPR's latest filing, up from $360.5 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $462.6 million in Q4 2025 to a low of $170.7 million in Q3 2021.
  • Average Current Assets over 5 years is $292.1 million, with a median of $283.0 million recorded in 2021.
  • Peak YoY movement for Current Assets: decreased 29.71% in 2021, then soared 68.1% in 2024.
  • A 5-year view of Current Assets shows it stood at $329.0 million in 2021, then fell by 25.01% to $246.7 million in 2022, then decreased by 18.49% to $201.1 million in 2023, then skyrocketed by 68.1% to $338.0 million in 2024, then skyrocketed by 36.86% to $462.6 million in 2025.
  • Per Business Quant, the three most recent readings for ESPR's Current Assets are $462.6 million (Q4 2025), $360.5 million (Q3 2025), and $342.6 million (Q2 2025).